Related Experiment Video
Updated: Mar 26, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Usefulness of ketogenic diet in a girl with migrating partial seizures in infancy
Tatsuo Mori1, Katsumi Imai1, Taikan Oboshi1
1National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Japan.
Insights
Migrating partial seizures in infancy (MPSI), a severe epilepsy syndrome, can be effectively managed with a ketogenic diet when antiepileptic drugs fail. This case report highlights the diet
Area of Science:
- Pediatric Neurology
- Epilepsy Syndromes
- Metabolic Therapies
Background:
- Migrating partial seizures in infancy (MPSI) is an age-specific epilepsy characterized by intractable focal seizures and severe developmental delay.
- Standard antiepileptic drugs (AEDs) are often ineffective in managing MPSI.
- The role of specific gene mutations, such as KCNT1, in MPSI treatment response is an area of ongoing research.
Observation:
- A 2-month-old infant presented with migrating focal seizures, initially unresponsive to multiple AEDs.
- The patient exhibited a heterozygous missense mutation in the KCNT1 gene.
- Partial response was noted with potassium bromide, but adverse effects limited its use.
Findings:
- Introduction of a ketogenic diet at 9 months of age led to significant improvement in seizure frequency and severity.
- The ketogenic diet was well-tolerated, with no significant adverse effects reported.
- This intervention allowed for the patient's discharge from the hospital.
Implications:
- The ketogenic diet represents a promising therapeutic option for infants with MPSI refractory to AEDs.
- Further research is needed to understand the differential treatment responses in MPSI patients with and without KCNT1 mutations.
- Accumulating case reports is crucial for establishing evidence-based treatment guidelines for MPSI.
Abstract:
Migrating partial seizures in infancy (MPSI) are an age-specific epilepsy syndrome characterized by migrating focal seizures, which are intractable to various antiepileptic drugs and cause severe developmental delay. We report a case of MPSI with heterozygous missense mutation in KCNT1, which was successfully managed by ketogenic diet. At age 2months, the patient developed epilepsy initially manifesting focal seizures with eye deviation and apnea, then evolving to secondarily generalized clonic convulsion. Various antiepileptic drugs including phenytoin, valproic acid, zonisamide, clobazam, levetiracetam, vitamin B6, and carbamazepine were not effective, but high-dose phenobarbital allowed discontinuation of midazolam infusion. Ictal scalp electroencephalogram showed migrating focal seizures. MPSI was suspected and she was transferred to our hospital for further treatment. Potassium bromide (KBr) was partially effective, but the effect was transient. High-dose KBr caused severe adverse effects such as over-sedation and hypercapnia, with no further effects on the seizures. At age 9months, we started a ketogenic diet, which improved seizure frequency and severity without obvious adverse effects, allowing her to be discharged from hospital. Ketogenic diet should be tried in patients with MPSI unresponsive to antiepileptic drugs. In MPSI, the difference in treatment response in patients with and those without KCNT1 mutation remains unknown. Accumulation of case reports would contribute to establish effective treatment options for MPSI.
More Related Videos
09:29Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists